No established evidence shows that smoking cannabis while taking naproxen creates a dangerous, life-threatening interaction, and you will not find this combination on any major drug-interaction warning list. That said, “not flagged as dangerous” and “totally fine” are not the same thing. The two substances share overlapping metabolic pathways in the liver, they both affect the same inflammatory signaling system, and they each carry gastrointestinal concerns that could compound in ways that have not been well studied in humans. The picture is more nuanced than a simple yes or no.
The Liver Enzyme Overlap
Naproxen is broken down in the liver primarily by an enzyme called CYP2C9. This is one of several enzymes responsible for clearing drugs from your system, and it matters here because cannabis compounds interfere with it. Lab studies using human cell preparations have shown that THC, CBD, and CBN all competitively inhibit CYP2C9. The major metabolites your body produces after consuming THC do the same thing, with one metabolite (11-hydroxy-THC) showing particularly strong inhibition of that enzyme.1Drug Metabolism and Disposition. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions
When an enzyme responsible for clearing a drug gets inhibited, the drug hangs around in your bloodstream longer and at higher concentrations than it otherwise would. In theory, smoking weed while taking naproxen could slow naproxen’s clearance, nudging its levels upward. Higher naproxen levels increase the risk of side effects, particularly stomach problems, kidney strain, and cardiovascular stress. Older rat studies also found that naproxen itself can alter liver enzyme activity, further complicating the metabolic picture.2PubMed. Effect of nonsteroidal anti-inflammatory drugs on the microsomal monooxygenase system of rat liver
The critical caveat is that these enzyme-inhibition findings come from lab-based (in vitro) experiments and modeling, not from clinical trials where people actually used both substances together. Lab studies can show that an interaction is biologically plausible without telling you how much it matters at real-world doses. The inhibition of CYP2C9 by cannabinoids is real, but whether the concentrations achieved through smoking a joint are enough to meaningfully change naproxen levels in a living person remains an open question. No one has run that clinical trial.
What Happens in the Stomach
Naproxen’s best-known side effect is stomach damage. All NSAIDs work by blocking cyclooxygenase (COX) enzymes, and while that reduces pain and inflammation, it also strips away some of the protective lining of the stomach. The result can be irritation, erosions, or in serious cases, bleeding ulcers. This is especially true when naproxen is taken at higher doses, for longer periods, or alongside alcohol.
Interestingly, animal research suggests cannabis may actually work against this particular risk rather than adding to it. In one mouse study, THC at a dose of 10 mg/kg significantly prevented gastric hemorrhages caused by the NSAID diclofenac, apparently by activating cannabinoid receptors in the gut lining.3The Journal of Pharmacology and Experimental Therapeutics. Inhibition of Monoacylglycerol Lipase Attenuates Nonsteroidal Anti-Inflammatory Drug-Induced Gastric Hemorrhages in Mice A separate rat study found that cannabis extract reduced stomach ulcers caused by indomethacin (another NSAID) in a dose-dependent manner, decreasing acid secretion and oxidative stress in the gastric tissue.4Journal of Basic Pharmacology and Toxicology. Effect of Cannabis sativa on the indomethacin-induced gastric mucosal damage
Before you take this as a green light, the research was done in rodents using controlled doses and purified compounds, not in people smoking commercially available cannabis alongside an over-the-counter painkiller. Animal GI protection from cannabinoids is a promising finding for future drug development, but it would be a stretch to conclude that smoking a bowl protects your stomach lining from naproxen. The doses, routes, and biology differ enough that the results do not translate directly. And smoking anything, cannabis included, introduces its own set of irritants to the body.
Do They Help Each Other With Pain?
One of the more intriguing angles in this area is the possibility that cannabinoids and NSAIDs enhance each other’s painkilling effects. Research in animal pain models has found that combining anandamide (the body’s own cannabis-like molecule) with ibuprofen produced synergistic pain relief, meaning the combination worked better than you would expect from just adding the two effects together. The interaction involved both major types of cannabinoid receptors.5Pain. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain
Ibuprofen and naproxen belong to the same drug class (both are propionic acid NSAIDs), so it is reasonable to suspect a similar synergy could exist with naproxen, though it has not been tested specifically. The practical implication people hope for is that combining the two might allow you to use a lower dose of the NSAID and still get adequate pain relief, reducing the risk of stomach damage and other side effects. That is a legitimate hypothesis, but it remains in the preclinical stage. No doctor is going to prescribe this combination on the basis of a mouse study.
Patient-reported data from a survey of people with hidradenitis suppurativa, a painful inflammatory skin condition, found that ibuprofen and naproxen were among the most commonly used pain treatments, while marijuana smoking received the highest average effectiveness rating from those who used it.6Journal of Dermatological Treatment. Pain management modalities for hidradenitis suppurativa: a patient survey Patients in that survey rated smoked marijuana slightly above even opioids for pain management. That is a subjective, self-reported finding from a specific population, and it does not prove anything about a naproxen-cannabis interaction in particular, but it does suggest that people dealing with chronic inflammatory pain often find cannabis helpful alongside conventional painkillers.
The COX Enzyme Crossover
Naproxen works by blocking COX-1 and COX-2, the enzymes that produce prostaglandins involved in inflammation and pain. It turns out that certain cannabis compounds also interact with these same enzymes. Cannabidiolic acid (CBDA), a raw precursor to CBD found in unheated cannabis, selectively inhibits COX-2 with roughly nine times more selectivity over COX-1.7PubMed. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis CBD itself has been shown to suppress the expression of both COX-1 and COX-2 at the genetic level in activated immune cells, though its direct enzyme-blocking effect is weaker than its effect on gene expression.8PubMed. Effect of Cannabidiol on Cyclooxygenase Type 1 and 2 Expression and Function in Human Neutrophils
This crossover matters for two reasons. First, it is one explanation for why cannabis has anti-inflammatory properties that go beyond just “getting high and forgetting about the pain.” Some components genuinely modulate the same inflammatory pathway that NSAIDs target. Second, having two substances both hitting the COX system could, in theory, produce an additive effect. Whether that additive effect is helpful (more anti-inflammatory power) or harmful (more suppression of protective prostaglandins in the gut and kidneys) depends on circumstances that have not been studied in controlled human trials.
The COX-2 selectivity of CBDA is worth noting because pharmaceutical companies spent billions developing selective COX-2 inhibitors like celecoxib (Celebrex) in the hope of reducing stomach side effects while preserving anti-inflammatory power. That a cannabis precursor compound shows similar selectivity is genuinely interesting, though CBDA is present mainly in raw, unheated cannabis and largely converts to CBD when smoked.
Smoking Versus Other Methods
How you consume cannabis changes the equation. Smoking delivers THC to the brain within minutes through the lungs, producing a rapid spike in blood THC levels that drops off relatively quickly. Edibles take longer to kick in but produce higher levels of the liver metabolite 11-hydroxy-THC, the same metabolite that potently inhibits CYP2C9 in lab studies.1Drug Metabolism and Disposition. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions So if CYP2C9 inhibition is the concern, edibles could theoretically pose a greater interaction risk than smoking, because your liver processes more of the THC on the first pass and generates more of the problematic metabolite.
On the flip side, smoking cannabis introduces combustion byproducts (tar, carbon monoxide, particulate matter) that have their own health costs, and chronic smoking can irritate the upper GI tract. If you are already taking a drug known for stomach irritation, adding smoke exposure to the mix is not ideal from a gastric standpoint, even if the cannabinoids themselves may be gastroprotective at the right doses.
Topical cannabis products and low-dose sublingual tinctures largely bypass liver metabolism and produce minimal systemic cannabinoid levels, making them the least likely to interact with naproxen in any pharmacologically meaningful way. For someone specifically worried about drug interactions but still wanting to use cannabis for pain or relaxation, these routes carry the lowest theoretical risk.
Who Should Be More Cautious
Certain groups face higher stakes from any potential interaction. If you are over 65, your liver and kidneys are already less efficient at clearing drugs, and naproxen levels tend to run higher even at standard doses. Adding anything that further slows naproxen metabolism could tip you closer to side effects. People with a history of stomach ulcers or GI bleeding should be careful with naproxen in the first place, and piling on any additional variable, cannabis included, adds uncertainty to an already risky situation.
People taking blood thinners like warfarin face a compounded concern, because warfarin is also metabolized by CYP2C9. If cannabis inhibits that enzyme, it could simultaneously raise levels of both warfarin and naproxen, and since both naproxen and warfarin independently increase bleeding risk, this combination deserves genuine caution.
Heavy, daily cannabis users are in a different metabolic situation than someone who smokes occasionally. Chronic use can lead to enzyme induction over time (the body ramps up certain metabolic pathways in response to repeated exposure), which might partially offset the acute inhibitory effects seen in lab studies. This does not mean chronic users are safe from interactions; it means their interaction profile may differ from occasional users in ways that have not been characterized.
Why There Are No Clear Guidelines
If you are frustrated by the vagueness of the answer here, the reason is straightforward: nobody has funded the studies that would give a definitive one. Cannabis remains a Schedule I substance under U.S. federal law, which has historically made clinical research extraordinarily difficult. Pharmaceutical companies have no financial incentive to study how a drug they already sell interacts with a substance they cannot patent. And academic researchers face bureaucratic hurdles, funding gaps, and regulatory barriers that make cannabis interaction studies much harder to conduct than studies of other drug-drug interactions.
The result is a landscape where lab studies clearly show biological plausibility for an interaction, animal models hint at both risks and potential benefits, patient surveys suggest people are combining these substances frequently and finding them effective, and yet no controlled trial has actually measured what happens to naproxen levels in a human being who smokes cannabis. This is not unique to naproxen. The same gap exists for cannabis interactions with most common medications. Pharmacists and doctors are left making educated guesses based on known metabolic pathways rather than direct evidence.
Alcohol, the Comparison Everyone Actually Wants
Most people asking whether they can smoke weed with naproxen have already heard the warning about mixing NSAIDs with alcohol, and they want to know if cannabis falls into the same category. The comparison is imperfect but instructive. Alcohol directly damages the stomach lining through its own mechanism, and when combined with an NSAID that is already suppressing protective prostaglandins, the result is a well-documented, dose-dependent spike in GI bleeding risk. Cannabis does not share alcohol’s direct mucosal toxicity; the animal data, as discussed earlier, actually points in the opposite direction.
Alcohol also stresses the liver in ways that can impair drug metabolism broadly, and it increases the risk of kidney damage when combined with NSAIDs. Cannabis does not cause liver damage at typical recreational doses (though very high-dose CBD supplements have been linked to liver enzyme elevations in some studies). So the combination of cannabis and naproxen is almost certainly less acutely dangerous than alcohol and naproxen, which is a low bar but a relevant one for people making practical decisions about a Friday night.
None of this amounts to medical advice, and the absence of a well-studied red flag is not the same as a green light. If you take naproxen regularly and also use cannabis, the most pragmatic approach is to keep your naproxen dose as low as effective, take it with food, watch for unusual stomach pain or dark stools (signs of GI bleeding), and mention both substances to your doctor or pharmacist so they can flag any additional risk factors in your specific situation. The honest answer is that most people combining these two substances are probably fine, but the science has not caught up to the point where anyone can say that with real confidence.